Patient care navigation and health copilot AI
Outcomes4Me
Outcomes4Me combines patient cancer education and trial discovery with a life-sciences business that offers sponsored content and recruitment. Commercial influence channels are documented. Their effect on actual treatment or trial rankings remains unverified.
Published September 8, 2026 as an AI-assisted draft. The public report separates documented facts, agency judgments and unresolved questions.
Summary judgment · 62 out of 100 toward patient-directed
Patient cancer navigation and trial discovery, with a separately disclosed life-sciences business. The two sets of interests coexist.
Mixed, strong patient education with sponsor-funded routing caveats
Outcomes4Me combines patient cancer education and trial discovery with a life-sciences business that offers sponsored content and recruitment. Commercial influence channels are documented. Their effect on actual treatment or trial rankings remains unverified.
Patient agency
How this tool changes agency
Guideline-derived education in the baseline expands the questions a patient can ask. Sponsor labeling in one public example is useful, but does not verify in-app treatment or trial ordering.
Live sponsored labeling, ranking, diagnosis correction and retention after withdrawal remain unverified
Patient agency assessment
Who sets and changes the goal?
The historical patient workflow lets people seek treatment information and trials. The current sponsor offering establishes a competing conversion objective, but does not demonstrate patients losing their final choice.
What can the patient understand, question, or do?
Guideline-derived education in the baseline expands the questions a patient can ask. Sponsor labeling in one public example is useful, but does not verify in-app treatment or trial ordering.
Can the patient evaluate the conditions of use?
Secondary uses are expressly disclosed. The critical question is whether patients can recognize and decline commercial influence while retaining useful navigation, not simply who funds the service.
Text findings
Conditions of use
Published controls and their limits
Secondary uses are expressly disclosed. The critical question is whether patients can recognize and decline commercial influence while retaining useful navigation, not simply who funds the service.
What remains unknown?
Not tested or not established
Live sponsored labeling, ranking, diagnosis correction and retention after withdrawal remain unverified
Who evaluated this?
AI-assisted public-source draft
Vendor statements describe published conditions, not independently verified behavior. No clinical, security, accessibility, or legal validation is claimed. Earlier evidence remains dated in the report and history.
Sources checked
Source-specific findings and retrieval limitations are recorded in the full report.
Review provenance
Criteria
CAIHL-derived HugoScore framework and September 7 qualitative review priorities. Draft v1.2 numerical anchors remain unadopted.
Reviewer
AI-assisted public-source reassessment prepared in OpenAI Codex.
AI / model
OpenAI Codex / GPT-6
Human review
Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
Review date
2026-09-08
Limitations
Live sponsored labeling, ranking, diagnosis correction and retention after withdrawal remain unverified No live product use, patient-data upload, account creation, code audit, clinical evaluation, or independent implementation validation.
Review method
Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
AI-assisted draft · Moderate for disclosed purposes and commercial offering (AI-assisted draft)